The Re-MIND clinical trial from the Nutrition Research Centre Ireland (NRCI) at South East Technological University, during which the ReMind™ supplement was used, has been published in the esteemed Journal of Alzheimer’s Disease (JAD).
The Editor-In-Chief, Prof George Perry (JAD), identified this study as newsworthy, saying “Re-MIND adds strong clinical evidence to the growing body of data supporting a key role for nutrition in reducing the incidence and slowing the progression of Alzheimer’s disease with supplements.”
Slower rates of disease progression, and greater improvements in mood and memory
Re-MIND (Memory Investigation with Nutrition for Dementia), a follow-on from a breakthrough study published by the NRCI in 2018, was a double-blind, placebo-controlled, clinical trial researching patients with mild to moderate stage Alzheimer’s disease.
It found that patients who consume three daily ReMind™ supplement capsules benefitted from this targeted nutritional intervention. Their blood concentrations of carotenoids, omega-3 fatty acids, and vitamin E all significantly increased after 12 months in comparison to patients receiving a placebo.
The main outcomes of the trial include slower rates of disease progression and greater improvements in mood and memory, as reported by the carers of patients receiving the active intervention.
The trial was led by Prof John Nolan and Dr Rebecca Power of the NRCI, working with Professor Ríona Mulcahy, Consultant Physician in General and Geriatric Medicine at University Hospital Waterford. The research team conclude that this supplement formulation should be used as part of the overall management of Alzheimer’s disease.
Exponential rise in Alzheimer’s disease
Commenting on the study, Prof Mulcahy said, “This works adds significantly to the accumulating body of evidence that good nutrition has a key role in the prevention or delay in onset of Alzheimer’s disease. The nutritional intervention in Re-MIND gives a specific combination of xanthophyll carotenoids, omega 3 fatty acids and vitamin E with resultant positive outcomes for people with Alzheimer’s disease. Given the exponential rise in the prevalence of Alzheimer’s disease, we need to optimise modifiable risk factors and evidence based nutritional advice should be considered in the overall-management.”
Supplementation can address nutritional deficiencies
The ReMind™ supplement, which is now patented in Ireland, the UK and the USA, contains protective active ingredients that are naturally found in the brain, but decrease with age and disease.
The ReMind™ formulation is a unique and natural nutritional blend of carotenoids, omega-3 fatty acids and vitamin E.
An earlier NRCI study reported that patients with Alzheimer’s disease are deficient in carotenoids compared to age-matched controls. The Re-MIND study showed that nutritional deficiencies in this population group can be addressed with supplementation.
ReMind™ supplement ingredients
ReMind™ reflects the very latest scientific understanding of brain nutrition and offers an over-the-counter, simple but effective addition to the overall management of a progressive disease of the brain, with no side-effects.
Omega-3 fatty acids are the building blocks of our cells (particularily in the brain), with DHA fatty acids making up 40% of our brain.
Carotenoids are plant-based pigments that give fruits and vegetables their colours. They have been discovered in both our eyes (at the macula) and our brain.
Vitamin E is one of four essential fat-soluble vitamins and has powerful anti-oxidant properties.
ReMind™ offers individuals an easy way to deliver a targeted daily boost of: 500mg Omega-3 DHA, 150mg Omega-3 EPA, 15mg Vitamin E, 10mg Lutein, 10mg Meso-Zeaxanthin, and 2mg Zeaxanthin to the brain.
The evidence-base
Explaining the evidence base behind the supplement, Professor Nolan says “The many scientific discoveries over the last two decades have led us to this point. Our earlier published studies clearly demonstrated that carotenoids are related to cognitive function in the general population across all ages. When combined with omega-3 fish oil we saw improved response of the carotenoids in blood, and that improvements in cognitive function can be achieved with supplementation of these nutrients. Then, we observed that these positive effects can also be achieved in individuals with mild cognitive impairment. In 2014, we reported that patients with Alzheimer’s disease have very low levels of carotenoids compared to aged-matched controls, so the results of the Re-MIND trial are compelling when all the evidence is considered.”
Speaking of the ReMind™ product launch, Professor Nolan stated, “We are delighted that the general population can now benefit from our scientific findings with the launch of the exact nutritional supplement formulation we used in the Re-MIND trial. Only by using nutritional supplements that have a scientific evidence base, with confirmed efficacy, and quality in terms of product stability and label claim will patients be able to benefit”.